Alizyme plc thinks its ATL-962lipase inhibitor to treat obesity may have better tolerability and similar efficacy to Xenical orlistat, a marketed lipase inhibitor from Roche, which has not been well accepted because
Read the full 339 word article
User Sign In
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury